These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 33901921)

  • 1. A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
    Clemons M; Fergusson D; Joy AA; Thavorn K; Meza-Junco J; Hiller JP; Mackey J; Ng T; Zhu X; Ibrahim MFK; Sienkiewicz M; Saunders D; Vandermeer L; Pond G; Basulaiman B; Awan A; Pitre L; Nixon NA; Hutton B; Hilton JF;
    Breast; 2021 Aug; 58():42-49. PubMed ID: 33901921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC).
    Clemons M; Mazzarello S; Hilton J; Joy A; Price-Hiller J; Zhu X; Verma S; Kehoe A; Ibrahim MF; Sienkiewicz M; Stober C; Vandermeer L; Hutton B; Mallick R; Fergusson D
    Support Care Cancer; 2019 Apr; 27(4):1345-1354. PubMed ID: 30099602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
    Skedgel C; Rayson D; Younis T
    Support Care Cancer; 2016 Jan; 24(1):387-394. PubMed ID: 26081595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
    Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
    Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review.
    Fernandes R; Mazzarello S; Stober C; Vandermeer L; Dudani S; Ibrahim MF; Majeed H; Perdrizet K; Shorr R; Hutton B; Fergusson D; Clemons M
    Breast Cancer Res Treat; 2017 Jan; 161(1):1-10. PubMed ID: 27783280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D.
    Lee EK; Wong WW; Trudeau ME; Chan KK
    Breast Cancer Res Treat; 2015 Feb; 150(1):169-80. PubMed ID: 25694355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer.
    Kimura Y; Sasada S; Emi A; Masumoto N; Kadoya T; Okada M
    Support Care Cancer; 2021 Jul; 29(7):3507-3512. PubMed ID: 33146835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis.
    Do T; Medhekar R; Bhat R; Chen H; Niravath P; Trivedi MV
    Breast Cancer Res Treat; 2015 Oct; 153(3):591-7. PubMed ID: 26337685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of primary granulocyte-colony stimulating factor prophylaxis on neutropenic toxicity and chemotherapy dose delivery in Chinese patients with breast cancer who received adjuvant docetaxel plus cyclophosphamide chemotherapy: a retrospective cohort study.
    Kwok CCH; Wong WH; Chan LL; Wong SPY; Wang F; Wong MCS; Tse SLA
    Hong Kong Med J; 2022 Dec; 28(6):438-446. PubMed ID: 36261264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of granulocyte-colony stimulating factor on docetaxel-induced febrile neutropenia in patients with breast cancer.
    Zekri J; Nawaz A; Rasool H; Ahmad I; Abdel Rahman H; Dada R; Abdelghany EM; Farag K; Ibrahim RB; Deibas MY; Kamel MK; Allithy A
    J Oncol Pharm Pract; 2022 Dec; 28(8):1681-1686. PubMed ID: 34342555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy.
    Chan A; Fu WH; Shih V; Coyuco JC; Tan SH; Ng R
    Support Care Cancer; 2011 Apr; 19(4):497-504. PubMed ID: 20232087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of an electronic tool in prescribing primary prophylaxis with ciprofloxacin or granulocyte colony-stimulating factor for breast cancer patients receiving TC chemotherapy.
    Sulpher J; Giguere P; Hopkins S; Dent S
    Support Care Cancer; 2016 Jul; 24(7):3185-9. PubMed ID: 26939922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
    Fust K; Li X; Maschio M; Villa G; Parthan A; Barron R; Weinstein MC; Somers L; Hoefkens C; Lyman GH
    Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost-effectiveness of primary prophylaxis with PEG-rhG-CSF in early-stage breast cancer patients receiving chemotherapy in China].
    Xia W; Wang SS; Hu H; Zhao FL; Xu F; Hong RX; Jiang KK; Yuan ZY; Shi YX; Zhao K; Huang JJ; Xue C; Bi XW; Lu QY; An X; Zhang JM
    Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):861-867. PubMed ID: 33113628
    [No Abstract]   [Full Text] [Related]  

  • 15. [Comparison of the Incidence of Febrile Neutropenia in Doxorubicin/Cyclophosphamide(AC)and Docetaxel/Cyclophosphamide(TC) Perioperative Chemotherapies for Primary Breast Cancer].
    Nohara Y; Ono S; Tanaka M; Yoshinaga Y; Ito T; Yamashita S; Iwasaki A
    Gan To Kagaku Ryoho; 2020 Nov; 47(11):1589-1591. PubMed ID: 33268733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer.
    Clemons M; Fergusson D; Simos D; Mates M; Robinson A; Califaretti N; Zibdawi L; Bahl M; Raphael J; Ibrahim MFK; Fernandes R; Pitre L; Aseyev O; Stober C; Vandermeer L; Saunders D; Hutton B; Mallick R; Pond GR; Awan A; Hilton J
    Ann Oncol; 2020 Jul; 31(7):951-957. PubMed ID: 32325257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Secondary Prophylactic G-CSF on the Occurrence of Febrile Neutropenia in Breast Cancer.
    Suzuki K; Sasada S; Kimura Y; Emi A; Kadoya T; Okada M
    Anticancer Res; 2022 Dec; 42(12):5945-5949. PubMed ID: 36456134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study.
    Sakurada T; Bando S; Zamami Y; Takechi K; Chuma M; Goda M; Kirino Y; Nakamura T; Teraoka K; Morimoto M; Tangoku A; Ishizawa K
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1107-1114. PubMed ID: 31502114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Febrile neutropenia in FEC-D regimen for early stage breast cancer: is there a place for G-CSF primary prophylaxis?
    Miguel I; Winckler P; Sousa M; Cardoso C; Moreira A; Brito M
    Breast Dis; 2015; 35(3):167-71. PubMed ID: 26406541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.
    Skoetz N; Bohlius J; Engert A; Monsef I; Blank O; Vehreschild JJ
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007107. PubMed ID: 26687844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.